Budget Impact Model of Cobimetinib in Combination with Vemurafenib For Previously Untreated Braf V600-Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
Abstract
Authors
D Kyriopoulos K Athanasakis A Akratos F Theodoropoulou X Caporis J Kyriopoulos